- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 31/415 - 1,2-Diazoles
Patent holdings for IPC class A61K 31/415
Total number of patents in this class: 4067
10-year publication summary
|
265
|
259
|
227
|
268
|
225
|
255
|
229
|
221
|
167
|
55
|
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Merck Sharp & Dohme Corp. | 2247 |
58 |
| The Regents of the University of California | 18943 |
54 |
| Bristol-myers Squibb Company | 5080 |
49 |
| Novartis AG | 11238 |
44 |
| Laboratorios Del Dr. Esteve, S.A. | 239 |
44 |
| Arena Pharmaceuticals, Inc. | 381 |
43 |
| Theravance Biopharma R&D IP, LLC | 550 |
38 |
| Allergan, Inc. | 2600 |
35 |
| Takeda Pharmaceutical Company Limited | 2961 |
30 |
| Merck Sharp & Dohme LLC | 3689 |
29 |
| Boehringer Ingelheim International GmbH | 4629 |
28 |
| AstraZeneca AB | 3042 |
27 |
| Janssen Pharmaceutica N.V. | 3839 |
27 |
| Vanderbilt University | 1731 |
27 |
| Epizyme, Inc. | 383 |
23 |
| Glaxosmithkline LLC | 566 |
22 |
| University of Southern California | 2016 |
22 |
| F. Hoffmann-La Roche AG | 7958 |
21 |
| Merck & Co., Inc. | 607 |
21 |
| Inflazome Limited | 92 |
21 |
| Other owners | 3404 |